Related references
Note: Only part of the references are listed.Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone
Jens Hoffmann et al.
CANCER RESEARCH (2008)
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone
S. Mani et al.
ANNALS OF ONCOLOGY (2007)
Paclitaxel: a review of adverse toxicities and novel delivery strategies
Neena I. Marupudi et al.
EXPERT OPINION ON DRUG SAFETY (2007)
Total synthesis and antitumor activity of ZK-EPO: The first fully synthetic epothilone in clinical development
Ulrich Klar et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors
EH Rubin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
SH Zhuang et al.
CANCER (2005)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
JA Low et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
